Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.96 |
| ▸ | HPGD | P15428 | 3/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MYC | P01106 | 1/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | DHFR | P00374 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MPO | P05164 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxytoluic Acid SCHEMBL30538824 | 1.00 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 | |
| Hydroxytoluic Acid SCHEMBL25756 | 0.98 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 | |
| Hydroxytoluic Acid SCHEMBL29499765 | 0.98 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 | |
| Hydroxytoluic Acid SCHEMBL8352264 | 0.98 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 | |
| Hydroxytoluic Acid SCHEMBL28037743 | 0.98 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 | |
| Hydroxytoluic Acid SCHEMBL25337502 | 0.96 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 | |
| Hydroxytoluic Acid SCHEMBL11527547 | 0.96 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 | |
| Hydroxytoluic Acid SCHEMBL31174935 | 0.96 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 | |
| Hydroxytoluic Acid SCHEMBL25338040 | 0.96 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 | |
| Hydroxytoluic Acid SCHEMBL238307 | 0.96 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024354-B | Preparation method of Rui Mi Buti Ni | 天津凯莱英制药有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-117024354-A | Preparation method of Rui Mi Buti Ni | 天津凯莱英制药有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-114989399-B | Room temperature Suzuki cross-coupling polymerization method of conjugated polymer semiconductor material | 中国科学院大学 | 2023-08-01 | — | — | CN | claimed |
| US-9060511-B2 | Compositions of dibromomalanomide and their use as biocides | ROHM AND HAAS COMPANY (US) | 2015-06-23 | — | — | US | claimed |
| EP-2582238-B1 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-06-04 | — | — | EP | claimed |
| US-20130142886-A1 | COMPOSITIONS OF DIBROMOMALANOMIDE AND THEIR USE AS BIOCIDES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-06-06 | — | — | US | claimed |
| EP-2582238-A1 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES | Dow Global Technologies LLC (US) | 2013-04-24 | — | — | EP | claimed |
| WO-2012021340-A1 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-02-16 | — | — | WO | claimed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119306724-A | Bicyclic substituted pyridazine derivative and application thereof | 正大天晴药业集团股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-118525017-A | Quinoline compounds as KRAS inhibitors | 因赛特公司 | 2024-08-20 | — | — | CN | disclosed |
| WO-2024080317-A1 | METHOD FOR PRODUCING HYDROXYBIOTIN DERIVATIVE AND VINYLBIOTIN DERIVATIVE | 株式会社トクヤマ | 2024-04-18 | — | — | WO | disclosed |
| CN-117024354-B | Preparation method of Rui Mi Buti Ni | 天津凯莱英制药有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117024354-A | Preparation method of Rui Mi Buti Ni | 天津凯莱英制药有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20130142886-A1 | COMPOSITIONS OF DIBROMOMALANOMIDE AND THEIR USE AS BIOCIDES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-06-06 | — | — | US | disclosed |
| EP-2582238-A1 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES | Dow Global Technologies LLC (US) | 2013-04-24 | — | — | EP | disclosed |
| WO-2013037626-A1 | ISOTHIAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| WO-2012021340-A1 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-02-16 | — | — | WO | disclosed |
| EP-1802590-A1 | SUBSTITUTED N-ALKYLPYRIMIDINONES | Pharmacia & Upjohn Company LLC (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040666-A1 | SUBSTITUTED N-ALKYLPYRIMIDINONES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142886-A1 | COMPOSITIONS OF DIBROMOMALANOMIDE AND THEIR USE AS BIOCIDES | DDT, BCHE, MGAM | ALDH1A1 1719/4885KDM4E 2395/4885HPGD 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.